STOCK TITAN

Akari Therapeutics plc (AKTX) Stock News

AKTX NASDAQ

Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.

Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) reported third-quarter 2026 results and initiated toxicology studies supporting its planned development of cancer candidate AKTX-101. Net loss narrowed to approximately $4.8 million from approximately $6.4 million a year earlier. Operating loss was approximately $4.7 million versus approximately $7.4 million; the prior-year quarter included a $5.2 million impairment charge. Cash was approximately $5.7 million at September 30, versus approximately $5.2 million at year-end 2025, following approximately $2.9 million in quarterly warrant proceeds.

Akari plans a mid-2027 Phase 1 trial, subject to additional financing. Preclinical urothelial cancer models showed tumor growth inhibition and activity after resistance to existing antibody-drug conjugates, which deliver payloads to tumors. A Whitehawk Therapeutics research collaboration will explore dual payloads using PH1. Early discovery work continues on AKTX-102.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) participated in a Virtual Investor “What This Means” video segment featuring newly appointed Chief Business Officer Vatnak Vat-Ho. The available discussion covers his oncology business development background and reasons for joining Akari.

Vat-Ho discusses the potential of the company’s PH1 payload platform and its application across antibody-drug conjugates, alongside his priorities for collaborations and investor engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) will present its RNA-splicing payload strategy at the ADC Payload Summit on November 6, 2026. Satyajit Mitra, Executive Director and Head of Oncology, will speak at 3:00 PM ET in Boston during the November 4–6 conference.

The presentation will examine antibody drug conjugates (ADCs) using PH1, a payload designed to disrupt RNA processing in cancer cells. In preclinical models, the approach demonstrated cancer-cell killing and activation of innate and adaptive immune responses. Expected topics include engineering considerations related to multidrug resistance, early translational findings and potential future combinations with immunotherapies. PH1 underpins Akari’s pipeline, including lead candidate AKTX-101, a TROP2-PH1 ADC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.00%
Tags
none
Rhea-AI Summary

Akari Therapeutics (AKTX) outlined its AKTX-101 development priorities in a new CEO Corner, targeting Phase 1 clinical development in mid-2027.

The company is advancing toxicology and safety studies needed for an investigational new drug application, large-scale manufacturing under good manufacturing practices, and Phase 1 planning. Its PH1 payload—the drug component of an antibody-drug conjugate, or ADC—is designed to disrupt RNA splicing in cancer cells through a mechanism distinct from commonly used ADC payload classes.

CEO Abizer Gaslightwala said differentiated payloads could become increasingly important as patients develop resistance to existing ADC payload classes. Akari is continuing discussions with potential strategic partners about PH1 and its potential to support a broader ADC pipeline. No completed partnership was announced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.43%
Tags
management clinical trial
-
Rhea-AI Summary

Akari Therapeutics (AKTX) appointed Vatnak Vat-Ho as Chief Business Officer to lead corporate strategy, partnering and licensing, and investor engagement.

Vat-Ho brings more than 20 years of experience across oncology business development, biopharmaceutical strategy, equity research and healthcare investing. He has led or held senior transaction roles in deals totaling more than $25 billion in aggregate value over his career. Most recently, as Chief Business Officer of Ryvu Therapeutics, he originated and closed an Exelixis collaboration involving a novel antibody drug conjugate payload and a multi-target immuno-oncology research collaboration with BioNTech.

His remit comes as Akari advances its lead TROP2-targeted antibody drug conjugate, AKTX-101, toward the clinic and develops its PH1 payload platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
none
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) has filed an international patent application expanding its intellectual property portfolio around PH1 and PH1-based antibody drug conjugates.

The application, PCT/US2026/45955, covers PH1’s modulation of alternative RNA splicing, a process that enables one gene to produce different protein versions. Its claims address pathways involved in tumor blood-vessel recruitment, programmed cell death and prostate cancer signaling. Antibody drug conjugates link an antibody to a drug payload. Akari believes PH1 has potential as a platform payload across multiple tumor targets and cancer types; the announcement concerns a patent filing, not a granted patent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
Rhea-AI Summary

Akari Therapeutics (AKTX) will present its PH1 antibody drug conjugate (ADC) payload platform and pipeline at five oncology, ADC and healthcare conferences in the United States and China during September 2026.

President and CEO Abizer Gaslightwala will deliver a keynote, fireside chat, formal presentations and join expert panels at events including the Oncology & Immunology Innovation Partnering & Licensing Summit (Boston, Sept. 9–10), H.C. Wainwright 28th Annual Global Investment Conference (virtual New York, Sept. 14–16), BioCon China 2026 (Shanghai, Sept. 15–16), Global XDC Innovation Conference (WuXi, Sept. 17–19) and the 5th Annual ROTH Healthcare Opportunities Conference (New York, Sept. 29).

Across these forums, Akari plans to highlight its PH1 payload’s RNA splicing–targeting mechanism, discuss AKTX-101 and AKTX-102, and explore collaboration and investment opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
none
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) announced its participation in the Virtual Investor “Why Now” on-demand conference held on August 27, 2026. President and CEO Abizer Gaslightwala presented the company’s investment thesis, focusing on the evolving antibody drug conjugate (ADC) market, demand for differentiated payload technologies, and Akari’s proprietary PH1 RNA splicing payload platform, which is designed to address limitations of conventional ADC payloads. The video webcast is available for on-demand viewing, and Akari notes that JTC Team and Virtual Investor Co. are paid investor relations and communications consultants. The company emphasizes the webcast does not constitute an offer to purchase securities and encourages investors to conduct their own due diligence via its website and SEC filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) reported new preclinical data for AKTX-101, a TROP2-targeted antibody-drug conjugate (ADC) carrying its novel PH1 RNA spliceosome-modulating payload, in urothelial cancer models representing metastatic disease and ADC-resistant tumors.

AKTX-101 showed statistically significant anti-tumor activity in the UM-UC-14 metastatic urothelial carcinoma model, where Padcev (enfortumab vedotin) had limited responsiveness, and slowed growth of tumors that had developed resistance to the first-generation TROP2 ADC Trodelvy (sacituzumab govitecan). According to Akari, these results support the potential of PH1 to address payload-specific resistance and enable differentiated ADC sequencing strategies as ADC use expands. The company is advancing IND-enabling work for AKTX-101, targeting a Phase 1 clinical trial start in mid-2027, and is pursuing additional tumor-specific programs and collaborations to broaden its PH1 payload platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
none
Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) reported second quarter 2026 financial results and progress on its lead ADC candidate AKTX-101. The company is conducting IND-enabling activities and remains focused on initiating a Phase 1 clinical trial in mid-2027, supported by manufacturing and development work.

Akari strengthened its balance sheet with approximately $8.6 million in gross financing during the quarter, including a $5.5 million private placement and $3.1 million from warrant exercises, resulting in about $8.0 million of net proceeds and cash of $7.7 million as of June 30, 2026.

The company entered a research collaboration with Whitehawk Therapeutics to explore dual-payload ADCs combining Akari’s PH1 spliceosome-modulating payload with Whitehawk’s topoisomerase I payload. Akari also presented preclinical data at ASCO 2026 showing synergistic anti-tumor activity of its PH1 payload with an approved KRAS inhibitor in KRAS-mutated pancreatic cancer models and expanded its international patent portfolio for the PH1 platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
partnership earnings clinical trial

FAQ

What is the current stock price of Akari Therapeutics (AKTX)?

Akari Therapeutics (AKTX) last closed at $7.18.

What is the market cap of Akari Therapeutics (AKTX)?

The market cap of Akari Therapeutics (AKTX) is approximately $16.7M.